Human papillomavirus genotype and oropharynx cancer survival in the United States of America

Marc T Goodman; Mona Saraiya; Trevor D Thompson; Martin Steinau; Brenda Y Hernandez; Charles F Lynch; Christopher W Lyu; Edward J Wilkinson; Thomas Tucker; Glenn Copeland; Edward S Peters; Sean Altekruse; Elizabeth R Unger

doi:10.1016/j.ejca.2015.09.005

Back

Human papillomavirus genotype and oropharynx cancer survival in the United States of America

Journal article

Peer reviewed

Human papillomavirus genotype and oropharynx cancer survival in the United States of America

Marc T Goodman, Mona Saraiya, Trevor D Thompson, Martin Steinau, Brenda Y Hernandez, Charles F Lynch, Christopher W Lyu, Edward J Wilkinson, Thomas Tucker, Glenn Copeland, …

European journal of cancer (1990), Vol.51(18), pp.2759-2767

12/2015

DOI: 10.1016/j.ejca.2015.09.005

PMID: 26602016

Files and links (1)

url

https://www.ncbi.nlm.nih.gov/pmc/articles/4666760View

Open Access

Abstract

The presence of human papillomavirus (HPV) DNA in oropharyngeal squamous cell cancer (OPSCC) tissue appears to be a strong predictor of improved prognosis, but this observation has not been explored in a population-based sample with generalisable findings. Follow-up data from a large sample of OPSCC patients identified through six population-based cancer registries in the United States of America (USA) were used to characterise the association of tumour HPV status with survival. HPV DNA was detected in tumour tissue from 71% (378 in 529) of the OPSCC patients. A total of 65% of patients with HPV16-associated tumours survived 5 years compared to 46% of patients with other HPV types and 28% of patients with HPV-negative tumours (p log-rank test <0.0001). The OPSCC patients with detectable HPV16 DNA had a 62% reduced hazard of death at 5 years, and patients with other HPV types had a 42% reduced hazard of death at 5 years compared to HPV-negative patients. Compared to non-Hispanic Whites, Blacks with OPSCC had a 2.6-fold greater risk of death at 5 years after adjustment for HPV status and other prognostic variables. Both surgery and radiation therapy were associated with a reduced 5-year risk of death, but no evidence was found for an interaction between HPV status and radiotherapy or surgery on survival time. Data from this US study suggest that HPV16-positive OPSCC patients survive longer than HPV-negative patients regardless of treatment, highlighting the prognostic importance of HPV status for this malignancy. Optimal treatment regimens for OPSCC could be tailored to each patient’s HPV status and prognostic profile. •Largest study was conducted regarding an association of human papillomavirus (HPV) status with oropharyngeal squamous cell cancer (OPSCC) prognosis.•Survival was significantly longer for HPV+ compared with HPV– OPSCC patients.•Five-year survival for HPV16+ OPSCC was higher compared to other high-risk HPV types.•The 2.6-fold greater risk of death among Blacks compared with non-Hispanic Whites with OPSCC persisted after adjustment for HPV status.

Human papillomavirus

Cancer registry

Survival

Cancer of the oropharynx

Archived tissue

Details

Title: Subtitle: Human papillomavirus genotype and oropharynx cancer survival in the United States of America
Creators: Marc T Goodman - Cancer Prevention and Control Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
Mona Saraiya - Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA
Trevor D Thompson - Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA
Martin Steinau - Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA
Brenda Y Hernandez - University of Hawaii Cancer Center, University of Hawaii, Honolulu, HI, USA
Charles F Lynch - Department of Epidemiology, College of Public Health, The University of Iowa, Iowa City, IA, USA
Christopher W Lyu - Battelle Memorial Institute, Durham, NC, USA
Edward J Wilkinson - Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA
Thomas Tucker - Department of Epidemiology, College of Public Health, University of Kentucky, Lexington, KY, USA
Glenn Copeland - Michigan Department of Community Health, Lansing, MI, USA
Edward S Peters - Department of Epidemiology, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA, USA
Sean Altekruse - Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD, USA
Elizabeth R Unger - Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA
Resource Type: Journal article
Publication Details: European journal of cancer (1990), Vol.51(18), pp.2759-2767
DOI: 10.1016/j.ejca.2015.09.005
PMID: 26602016
NLM abbreviation: Eur J Cancer
ISSN: 0959-8049
eISSN: 1879-0852
Publisher: Elsevier Ltd
Grant note: name: Centres for Disease Control and Prevention, award: 5U58DP000810-5, 5U58DP000844-5, 5U58DP000812-5, 5U58DP000769-5; DOI: 10.13039/100000002, name: National Institutes of Health, award: N01-PC-35143, N01-PC-35137
Language: English
Date published: 12/2015
Academic Unit: Epidemiology
Record Identifier: 9983995061802771

Metrics

31 Record Views

75 Times Cited - Web of Science